KCNJ2
MOLECULAR TARGETpotassium inwardly-rectifying channel, subfamily J, member 2
KCNJ2 (potassium inwardly-rectifying channel, subfamily J, member 2) is targeted by 16 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting KCNJ2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Masoprocol | 1.39 | 3 |
| 2 | Putrescine | 1.10 | 2 |
| 3 | Spermine | 1.10 | 2 |
| 4 | Thioridazine | 1.10 | 2 |
| 5 | Duloxetine Hydrochloride | 0.69 | 1 |
| 6 | Sertraline | 0.69 | 1 |
| 7 | Spermidine | 0.69 | 1 |
| 8 | Astemizole Antihistamine drug now withdrawn from | 0.69 | 1 |
| 9 | Carvedilol | 0.69 | 1 |
| 10 | Chlorhexidine | 0.69 | 1 |
| 11 | Disulfiram | 0.69 | 1 |
| 12 | Nisoldipine | 0.69 | 1 |
| 13 | Perphenazine | 0.69 | 1 |
| 14 | Salmeterol Xinafoate | 0.69 | 1 |
| 15 | triflupromazine hydrochloride | 0.69 | 1 |
| 16 | Zearalenone (S-(E))-3,4,5,6,8,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradec in-1,7(8H)-dione. | 0.69 | 1 |
About KCNJ2 as a Drug Target
KCNJ2 (potassium inwardly-rectifying channel, subfamily J, member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 16 compounds with documented KCNJ2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
KCNJ2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.